Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of … Read more

Medicare releases prices for first 10 drugs subject to negotiations

Medicare releases prices for first 10 drugs subject to negotiations

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images The Biden administration on Thursday will release prices for the first 10 prescription drugs that were subject to landmark negotiations between drugmakers and … Read more

Drugmakers on new negotiated prices with Medicare

Drugmakers on new negotiated prices with Medicare

President Joe Biden speaks during an event at the National Institutes of Health in Bethesda, Maryland, Dec. 14, 2023. Chris Kleponis | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round of Medicare drug price negotiations has come … Read more

First Medicare drug price negotiations round nears end

First Medicare drug price negotiations round nears end

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The first round … Read more

This up-and-coming cancer treatment could be a $25 billion market opportunity

This up-and-coming cancer treatment could be a  billion market opportunity

Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 … Read more

Google’s Demis Hassabis tasked with turning AI research into profits

Google’s Demis Hassabis tasked with turning AI research into profits

Demis Hassabis is a celebrated name in artificial intelligence research. He’s a chess master and a neuroscientist. On Wall Street, he’s less known. That may not be true for long. Hassabis is emerging as the face of Google’s mammoth AI effort and on Tuesday will take the stage at the annual developer’s conference, Google I/O, … Read more

FTC challenges patents held by drugmakers, including for Ozempic

FTC challenges patents held by drugmakers, including for Ozempic

A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023.  Lee Smith | Reuters The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster diabetes drugs Ozempic, Saxenda and Victoza. … Read more

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024.  Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs … Read more

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024.  Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs … Read more

What Jim Cramer is watching to see where the stock market goes next

What Jim Cramer is watching to see where the stock market goes next

We don’t know what we want. This week, we will find out what it is that will propel us forward or turn us back after the S & P 500 on Friday closed at a new record high for the first time in more than two years. For example, we have three rails that report … Read more